Finance
2025.10.20
Lumosa Announces Details of Upcoming 2025 Institutional Investor Conference
Corporate
2025.10.17
Announcement: Change in Company Spokesperson
Finance
2025.09.19
Lumosa Submits LT3001 Phase 3 Trial Consultation to the US FDA
Finance
2025.04.21
Lumosa Licenses the “T-Cell Enhancement Technology” from UNC
Finance
2025.03.10
Lumosa Ends Phase 2 Trial Early to Facilitate EOP2 Meeting for LT3001 with US FDA
Finance
2024.12.05
Media Report Clarification